Athersys (NASDAQ:ATHX) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a note issued to investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys has a 52 week low of $0.01 and a 52 week high of $1.99. The stock has a market capitalization of $833,000.00, a PE ratio of -0.01 and a beta of -0.90.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.